Skip to content

Atropine sulfate/Edrophonium cl

    Brands

    DEA Class;  Rx

    Common Brand Names; Enlon Plus

    • Antidotes, Systemic

    Combined cholinesterase inhibitor, edrophonium, and antimuscarinic agent, atropine
    Used IV to reverse the effects of nondepolarizing neuromuscular blocking agents (e.g., curare type)
    Edrophonium exerts the primary actions, while atropine decreases the adverse reactions associated with edrophonium

    For use in nondepolarizing neuromuscular blockade reversal or antagonism, or as an adjunctive treatment of respiratory depression due to curare overdosage.

    Glaucoma, posterior synechiae, synechia

    GI obstruction, pyloric stenosis, toxic megacolon

    Sulfite hypersensitivity

    AV block 
    Bradycardia 
    Arrhythmia exacerbation 
    Respiratory arrest 
    Laryngospasm
    Seizures 
    Scarlatiniform Exanthema 

    Premature ventricular Contractions (PVCs) 
    Sinus tachycardia 
    Dysphonia 
    Dysarthria 
    Dysphagia
    Conjunctival hyperemia 
    Photophobia 
    Blurred vision 
    Urinary retention

    Bronchial secretions 
    Restlessness 
    Weakness
    Asthenia

    Abdominal pain 
    Vomiting 
    Nausea 
    Diarrhea 

    –

    Atropine; edrophonium is classified as FDA pregnancy risk category C

    According to the manufacturer, the safety and efficacy of atropine; edrophonium during breast-feeding has not been established.

    Adults

    0.014 mg atropine; 1 mg edrophonium per kg IV per dose.

    Geriatric

    0.014 mg atropine; 1 mg edrophonium per kg IV per dose.

    Adolescents

    Safety and efficacy have not been established.

    Children

    Safety and efficacy have not been established.

    Infants

    Safety and efficacy have not been established.

    Neonates

    Safety and efficacy have not been established.

    Enlon Plus Intravenous Inj Sol: 1mL, 10-0.14mg